80 results
8-K
EX-99.1
ENTA
Enanta Pharmaceuticals Inc
6 May 24
Results of Operations and Financial Condition
4:05pm
. This decrease was partially offset by increased costs associated with Enanta’s RSV programs and its recently announced immunology programs.
General
S-3
ENTA
Enanta Pharmaceuticals Inc
22 Nov 23
Shelf registration
4:38pm
will represent an interest in two or more other securities, which may or may not be separable from one another.
Table 2: Fee Offset Claims and Sources …
Registrant
or Filer
Name
Form
or
Filing
Type
File
Number
Initial
Filing
Date
Filing
Date
Fee
Offset
Claimed
Security
Type
Associated
with Fee
8-K
EX-99.1
s0fqn0ve
20 Nov 23
Results of Operations and Financial Condition
4:05pm
8-K
EX-99.1
dq6yte
7 Aug 23
Results of Operations and Financial Condition
4:06pm
8-K
EX-10.1
cabo74
27 Apr 23
Non-Dilutive and Strengthens Balance Sheet
4:43pm
8-K
EX-99.1
0pol 0qsie3trux8
21 Nov 22
Results of Operations and Financial Condition
4:08pm
8-K
EX-99.1
f0uh rh113mb
8 Aug 22
Results of Operations and Financial Condition
4:04pm
8-K
EX-10.3
7sm8qzpzguiej z6mw
17 May 22
Entry into a Material Definitive Agreement
4:37pm
8-K
EX-10.2
dk18b6 kb
17 May 22
Entry into a Material Definitive Agreement
4:37pm
8-K
EX-99.1
6roo4d
9 May 22
Expects Topline Data From RSVP, a Phase 2b Study of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Virus (RSV), This Quarter
4:00pm
8-K
EX-99.1
vucqtem hdq7k90qp
8 Feb 22
Results of Operations and Financial Condition
1:44pm